Legacy Research Group

Teeka Tiwari just pulled back the curtain on his next “trillion-dollar trade” – psychedelic medicine.

Teeka has been on the money twice already. His last two trillion-dollar ideas were investing in Apple after it launched the iPod in 2003… and buying bitcoin in 2016.

He says psychedelic medicine is the next massive market megatrend in the making. And that it has the potential to hand investors 100 years of S&P 500 returns… in just 18 months.

But what is psychedelic medicine? What is it used for? And why is Teeka so excited?

It’s all in your Weekly Pulse video update at the top of the page. It’s where I (Chris Lowe) and host Tom Beal break down the most important story on our radar for the week.

Regards,

Chris Lowe
Editor, The Daily Cut and Legacy Inner Circle

P.S. To watch the replay of Teeka’s event all about psychedelic medicine and how to play this emerging megatrend, go here. 

P.P.S. To catch up on some previous Daily Cut dispatches we’ve written on the topic of psychedelic medicine, click here and here.

Transcript

Tom Beal: Teeka Tiwari has called this the biggest breakthrough since biotech. Imagine a way for you to grow and protect your wealth, while helping people immensely with depression, post-traumatic stress disorder (PTSD), and saving many people from suicide. That’s our topic for today.

My name is Tom Beal, host of the Weekly Pulse, where we bring to you and break down the biggest wealth-growth story of the week.

I’m here today with the editor of Legacy Inner Circle, Chris Lowe. Chris, how do we kick off today’s conversation?

Chris Lowe: Tom, this week, we’re going to be talking about what Teeka Tiwari, our colleague at Legacy Research, thinks is the biggest breakthrough since biotech. That’s actually one of the quotes he’s had, so this is a really big deal.

What he’s talking about is something called psychedelic medicine. That may sound kind of strange. Psychedelics are often associated with the 1960s and with the hippie movement. But this has nothing to do with that.

So today, I thought we’d talk about what psychedelic medicine is. Then we’ll talk about what it’s used for, and why Teeka is so excited about this new breakthrough in medicine.

Tom: Chris, it reminds me of Prohibition of the past, where alcohol was illegal. Then it became legal. And then cannabis, which was illegal and now is becoming legal in many states. So this is another aspect of that that I’m excited to discuss today.

Chris: Tom, it’s a really good point. This is another of those brand-new markets that’s just opening up. It’s really rare. Cannabis started to become legal in certain states in the U.S. and then across Canada. It’s just this once-in-a-lifetime opportunity.

Now, when we say once-in-a-lifetime opportunity, it sounds clichéd. But this really is. You have these substances, compounds that are illegal, thanks to some pretty dodgy federal government stomping all over people’s rights. And then suddenly, they become legal.

And you’re right. Cannabis did this. And now, psychedelic medicine is doing the same thing.

For folks who aren’t familiar with that term, what is psychedelic medicine? It’s therapeutic compounds that have been isolated from psychedelic drugs. These include things like MDMA, which is the key ingredient of a party drug that people may be familiar with called ecstasy. And we also have psilocybin, which is the active compound in certain types of mushrooms, often called magic mushrooms. And even a close cousin of ketamine, which is a party drug, called Super K.

If you’re at a party on the streets in America, or Europe, where I am, you can buy these as party drugs. But actually, researchers are finding out that the compounds they contain have these really powerful properties.

So what are these things used for? This is where it gets really interesting, Tom. Because the FDA, the Food and Drug Administration, which is responsible for green-lighting new therapies in the U.S., has granted breakthrough therapy status to MDMA-assisted psychotherapy for post-traumatic stress disorder (PTSD).

Tom, I know you served in the Marines. 20 active duty and retired military personnel take their own lives every day. That sounded shocking to me. These compounds used with therapy are helping folks get over that type of trauma in their lives.

Tom: That’s why this topic excites me so much. Yes, I have a personal vested interest, being someone who served in the United States Marine Corps. And also in witnessing the amount of people that are choosing to take their lives because of post-traumatic stress disorder and other things.

If this can help people get out of that dark spot they’re in, to find some more light at the end of the tunnel and live their life, this is really exciting and a huge breakthrough for me.

How can this help you grow and protect your wealth in the future? That’s why we’re here today. If you can tie in helping people in a great way with this new thing that used to be illegal and is now not illegal… and it can help people in tremendous ways… and you can grow and protect your wealth, it’s a win on all sides, from my perspective.

Chris: And it’s not just PTSD that these compounds are being used to treat. It’s also depression, which is a really big problem across the world.

The FDA has also granted breakthrough therapy designation for psilocybin. That’s the compound from magic mushrooms. That’s to treat treatment-resistant depression (TRD), which means that regular pharmaceutical drugs aren’t working on these folks. But with therapy-assisted psilocybin, they can actually get beyond that depression.

This is already breaking into the mainstream, Tom. It’s amazing how fast this is moving. Johnson & Johnson (JNJ), the pharmaceutical giant, recently released its own FDA-approved drug called Spravato to treat people suffering from depression.

That is using a compound from a close cousin of a party drug called ketamine to treat depression. It’s a fast-acting nasal spray. And that’s also getting FDA approval, moving into the mainstream, and being effective in treating depression, which is very, very exciting.

And, Tom, just to your point about military personnel in the U.S., active and retired. The U.S. Department of Veterans Affairs has approved ketamine for the treatment of PTSD.

These are huge breakthroughs. These illnesses – PTSD and depression – cause a lot of suffering, as you know. So as Teeka says, these are the biggest breakthroughs since biotech, because they’re treating these mental health issues that have been so difficult to treat up to now.

Tom: So, Chris, now that we’re aware of this and it’s becoming more mainstream, how and where would you recommend the viewers of The Weekly Pulse research this and see how it could be a component in growing and protecting their wealth in the future?

Chris: That’s a great question, Tom. Look, this is very early on still, in terms of being investible. We did have some success at Legacy Research. Subscribers of another of our analysts, Nick Giambruno over at Casey Research, had the chance to make a gain on a tiny psychedelic medicine stock called Mind Medicine (MMED) last year.

Nick recommended it to his Crisis Investing subscribers in March 2020. When he sent out a sell alert in December 2020, it was up 1,282%. I remember writing about it last December. It was the best-performing stock across all of Legacy last year.

Now, Teeka has set up a new advisory service called Palm Beach Special Opportunities to look at the psychedelic medicine trend and other trends in the future. That’s how excited he is.

He has brought on Mike Zapolin, who’s known as the “psychedelic concierge to the stars.” He’s a former Wall Street banker, who has been featured in Vice and Playboy and Fox News. He’s been in this space for a long time. He and Teeka are really digging into these tiny stocks.

Right now, Tom, the universe of stocks in this space is very small. These aren’t major stocks trading on exchanges. So this is really something for the radar right now.

Teeka will be looking at these a lot more. And we’ll have some links below, Tom. If anyone wants to find out more about psychedelic medicine, I think the best thing right now is to click on the links we provide below.

Teeka had a live event last Thursday. He revealed a lot more details than we’re able to go into here. And he had his new right-hand man, Mike Zapolin, on there, along with a bunch of stars that have gone down the road of psychedelic treatments. That’s a really interesting replay that folks can catch.

And then, it’s just a matter of watch this space. There’s going to be small stocks getting bigger, and we’ll be covering them in the weeks and months ahead.

Right now, there isn’t a specific recommendation I’m going to pass on, other than to catch up on Teeka’s event. He’s going to have a lot more details for folks who want to dig into this trend some more.

[Click here to watch the replay of Teeka’s “Third Trillion-Dollar Trade” event.]

Tom: Wow! That is helpful. I know some people who did have depression and some serious issues, PTSD and others, a whole bunch of issues. They went down the psychedelic path. I’ve never gone that path, but I’ve heard friends say it changed their life.

So I’m excited that this is something that can be beneficial to those needing it for depression and the things we discussed.

But I’m also excited about it being something to have on the radar for me and all the viewers of The Weekly Pulse to say, “Okay, let me start doing some research.”

What’s the old saying? Skate to where the puck is going, not where it is or where it’s been. So this is where the puck is going. And there’s a great way to possibly grow and protect your wealth.

And the other thing is, if Teeka is excited about this, that gets me super excited. I’ve done very well following what Teeka recommends. And I think many here watching this can agree. So that gets me even more excited, that there’s a way to see how and what Teeka is doing with this new possibility. So thanks for sharing that with us today, Chris.

Chris: Tom, one last thing before we sign off. Teeka says this is going to be a $3 trillion industry. That’s because that’s the kind of spend that’s happening right now on PTSD and depression, two of the biggest mental health issues in the U.S.

So this market is going to take a huge chunk out of that overall market of $3 trillion.

So this really is, as you say, where the puck is going, in terms of mental health. Teeka is convinced about it. I have seen him very excited about things before, like crypto back in 2016, when he was recommending bitcoin. He has put a lot of work into this. He’s partnered up with Mike Zapolin, who’s one of the leaders in this space.

And he’s really putting his name and his reputation behind this being one of the next big market megatrends that a lot of people are going to be hearing about in one year’s time, two years’ time.

So you heard it here first. For a lot of folks viewing, this will be the first time they’ve heard it. But it won’t be the last.

Tom: Chris, now it’s on my radar. I’m going to make a little ticker to start doing some research and keep my eyes open. And most importantly, plug into what Teeka’s saying. Because as we all know, what Teeka says generally work. So I’m going to be listening very closely.

Thanks for bringing that to my and the viewers of the Weekly Pulse’s attention today, Chris. We’re excited to look further into that.

Chris: Thanks, Tom.

Not yet a Legacy Inner Circle member? Join here.